

FILE 'USPAT2' ENTERED AT 13:20:11 ON 17 NOV 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 13:20:11 ON 17 NOV 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 13:20:11 ON 17 NOV 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 13:20:11 ON 17 NOV 2005
COPYRIGHT (C) 2005 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 13:20:11 ON 17 NOV 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 13:20:11 ON 17 NOV 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s affinity purification and troponin and affinity ligands and protein tags
14 FILES SEARCHED...
25 FILES SEARCHED...
33 FILES SEARCHED...
49 FILES SEARCHED...
60 FILES SEARCHED...

L1 1 AFFINITY PURIFICATION AND TROPONIN AND AFFINITY LIGANDS AND
PROTEIN TAGS

=> d L1

L1 ANSWER 1 OF 1 USPATFULL on STN
AN 2005:50709 USPATFULL
TI **Affinity purification** system using **troponin**
molecules as **affinity ligands**
IN Moeckli, Randolph A., San Carlos, CA, UNITED STATES
Chadwick, Christopher C., West Chester, PA, UNITED STATES
PI US 2005043510 A1 20050224
AI US 2004-820998 A1 20040407 (10)
PRAI US 2003-462483P 20030410 (60)
DT Utility
FS APPLICATION
LN.CNT 2139
INCL INCL: 530/344.000
NCL NCL: 530/344.000
IC [7]
ICM: C12P021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:19:59 ON 17 NOV 2005)

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHDS, BIOTECHNO,
CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU,
DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, ...' ENTERED AT 13:20:11 ON 17
NOV 2005

L1 1 S AFFINITY PURIFICATION AND TROPONIN AND AFFINITY LIGANDS AND P

=> s affinity purification and troponin C and matrix
21 FILES SEARCHED...
34 FILES SEARCHED...
58 FILES SEARCHED...

L2 58 AFFINITY PURIFICATION AND TROPONIN C AND MATRIX

=> dup rem

ENTER L# LIST OR (END):L2
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L2
L3 52 DUP REM L2 (6 DUPLICATES REMOVED)

=> d L3 1-52 ibib,abs

L3 ANSWER 1 OF 52 IFIPAT COPYRIGHT 2005 IFI on STN DUPLICATE 1
AN 10804799 IFIPAT;IFIUDB;IFICDB
TITLE: AFFINITY PURIFICATION SYSTEM
USING TROPONIN MOLECULES AS AFFINITY LIGANDS
INVENTOR(S): Chadwick; Christopher C., West Chester, PA, US
Moeckli; Randolph A., San Carlos, CA, US
PATENT ASSIGNEE(S): Unassigned
PATENT ASSIGNEE PROBABLE: Aristex Inc (Probable)
AGENT: MORRISON & FOERSTER LLP, 755 PAGE MILL RD, PALO ALTO,
CA, 94304-1018, US

	NUMBER	PK	DATE
PATENT INFORMATION:	US 2005043510	A1	20050224
APPLICATION INFORMATION:	US 2004-820998		20040407

	NUMBER	DATE
PRIORITY APPLN. INFO.:	US 2003-462483P	20030410 (Provisional)
FAMILY INFORMATION:	US 2005043510	20050224
DOCUMENT TYPE:	Utility	
	Patent Application - First Publication	
FILE SEGMENT:	CHEMICAL	
	APPLICATION	

PARENT CASE DATA:

This application claims the benefit of U.S. Provisional Application No.
60/462,483, filed on Apr. 10, 2003, the disclosure of which is incorporated by
reference in its entirety herein.

NUMBER OF CLAIMS: 66 11 Figure(s).
DESCRIPTION OF FIGURES:

FIG. 1 schematically illustrates a troponin affinity tag and capture system of
this invention in an embodiment in which a **troponin C**
fusion protein is purified on a **troponin C** binding peptide
affinity **matrix**.

FIG. 2 illustrates key features of an embodiment of a **troponin**
C expression vector. PrT7 refers to the T7 promoter, T refers to a
thrombin recognition site, and MCS refers to a multiple cloning site.

FIG. 3 shows a Coomassie blue stained SDS-PAGE gel of a **troponin**
C (TnC)-Jol purification. A 12.5% Laemmli mini-gel was used with a
sample load of 5 μ L on a **troponin C** binding peptide
(TBP)-agarose column. Lane 1 shows the column load, lane 2 is representative of
the column flow-through fractions, lane 3 represents the column wash, and lanes
4-8 represent fractions from the elution after addition of EDTA.

FIG. 4 shows a Coomassie blue stained SDS-PAGE gel of a purification of a
TnC-La Delta C (rabbit skeletal muscle **troponin C** fused to
the N-terminus of a C-terminal truncated version of the human La/SSB autoimmune
antigen) fusion protein on a TBP-agarose column. A 12.5% Laemmli mini-gel was
used with a sample load of 5 μ L. Lane 1 shows the column load, lanes 25 show
column flow-through fractions; lanes 6-8 show column wash fractions, and lanes
9-14 show fractions from the elution after addition of EDTA.

FIG. 5 shows a Coomassie blue stained SDS-PAGE gel that illustrates the
purification of a **troponin C**-tagged full length La/SSB on a
TBP-agarose column. A 12.5% Laemmli mini-gel was used with a sample load of 5
 μ L. Lane 1 shows the column load, lanes 2-5 show column flow-through
fractions, lanes 6-8 show column wash fractions, and lanes 9-14 show fractions

from the elution after addition of EDTA.

FIG. 6 shows an SDS PAGE gel of TBP-La/SSB (lane 1), TnC-Jo1 (lane 2), TnC-La Delta C (lane 3), and TnC-La/SSB (lane 4), together with a corresponding Western blot probed with an antirabbit skeletal muscle **troponin** ***C*** antibody.

FIG. 7 illustrates key features of an embodiment of a TBP expression vector. PrT7 refers to the T7 promoter and MCS refers to the multiple cloning site.

FIG. 8 shows a Coomassie blue stained SDS-PAGE gel that illustrates the purification of a **troponin C** binding peptidetagged

C-terminal truncated La/SSB fusion protein on a **troponin C**

-sepharose column. A 12.5% Laemmli mini-gel was used with a sample load of 5 μ L. Lane 1 shows the column load, lanes 2-5 show column flow-through fractions, lanes 6-8 show column wash fractions, and lanes 9-14 show fractions from the elution after addition of EDTA.

FIG. 9 shows a Coomassie blue stained SDS-PAGE gel that illustrates the purification of **troponin C**-tagged Ro52 on a troponin

I-agarose column in the presence of 8M urea. Lane 1 shows the column load, lanes 2-4 show flow-through fractions, lanes 5-10 show column wash fractions, and lanes 11-15 show fractions of the elution after addition of EDTA.

FIG. 10 shows a comparison between purification of (A) Histagged La antigen (His-La) and (B) **troponin C**-tagged C-terminal truncated La antigen (TnC-La Delta C). Lane 1 shows the column load, lane 2 shows column flow-through, and lane 3 shows the peak fraction of eluted fusion protein. Arrows to the right of the figure illustrate breakdown products or incomplete translation products of the TnC-La Delta C fusion protein.

FIG. 11 shows a Coomassie blue stained SDS-PAGE gel that illustrates thrombin protease cleavage of a **troponin C**-tagged La Delta C molecule (TnC-La Delta C). Lane 1 shows untreated TnC-La Delta C. Lanes 2-5 illustrate thrombin cleavage of the fusion protein with increasing amounts of thrombin. Lane 5 demonstrates complete cleavage of the TnC tag from La Delta C. Lane 1: no thrombin. Lane 2: 0.0125 units thrombin. Lane 3: 0.025 units thrombin. Lane 4: 0.05 units thrombin. Lane 5: 0.1 units thrombin.

AB This invention pertains to the use of a novel set of tags for the immobilization and/or purification of proteins or other biological or organic molecules. The invention provides **troponin C**, **troponin C** binding peptide, and troponin I, or active fragments or analogues thereof as convenient tags and affinity ligands for immobilizing, attaching, or purifying proteins or other molecules. Methods for producing troponintagged molecules, such as recombinant fusion proteins, are described. Methods for preparing a troponin affinity **matrix** that is capable of specifically binding its cognate ligand in the presence of calcium, and methods for using such a **matrix** to purify troponin-tagged molecules are also described.

CLMN 66 11 Figure(s).

FIG. 1 schematically illustrates a troponin affinity tag and capture system of this invention in an embodiment in which a **troponin C** fusion protein is purified on a **troponin C** binding peptide affinity **matrix**.

FIG. 2 illustrates key features of an embodiment of a **troponin C** expression vector. PrT7 refers to the T7 promoter, T refers to a thrombin recognition site, and MCS refers to a multiple cloning site.

FIG. 3 shows a Coomassie blue stained SDS-PAGE gel of a **troponin C** (TnC)-Jo1 purification. A 12.5% Laemmli mini-gel was used with a sample load of 5 μ L on a **troponin C** binding peptide (TBP)-agarose column. Lane 1 shows the column load, lane 2 is representative of the column flow-through fractions, lane 3 represents the column wash, and lanes 4-8 represent fractions from the elution after addition of EDTA.

FIG. 4 shows a Coomassie blue stained SDS-PAGE gel of a purification of a TnC-La Delta C (rabbit skeletal muscle **troponin C** fused to the N-terminus of a C-terminal truncated version of the human La/SSB autoimmune antigen) fusion protein on a TBP-agarose column. A 12.5% Laemmli mini-gel was used with a sample load of 5 μ L. Lane 1 shows the column load, lanes 2-5 show column flow-through fractions; lanes 6-8 show column wash fractions, and lanes 9-14 show fractions from the elution after addition of EDTA.

FIG. 5 shows a Coomassie blue stained SDS-PAGE gel that illustrates the purification of a **troponin C**-tagged full length

La/SSB on a TBP-agarose column. A 12.5% Laemmli mini-gel was used with a sample load of 5 μ L. Lane 1 shows the column load, lanes 2-5 show column flow-through fractions, lanes 6-8 show column wash fractions, and lanes 9-14 show fractions from the elution after addition of EDTA. FIG. 6 shows an SDS PAGE gel of TBP-La/SSB (lane 1), TnC-Jo1 (lane 2), TnC-La Delta C (lane 3), and TnC-La/SSB (lane 4), together with a corresponding Western blot probed with an antirabbit skeletal muscle **troponin C** antibody.

FIG. 7 illustrates key features of an embodiment of a TBP expression vector. PrT7 refers to the T7 promoter and MCS refers to the multiple cloning site.

FIG. 8 shows a Coomassie blue stained SDS-PAGE gel that illustrates the purification of a **troponin C** binding peptidetagged C-terminal truncated La/SSB fusion protein on a **troponin C**-sepharose column. A 12.5% Laemmli mini-gel was used with a sample load of 5 μ L. Lane 1 shows the column load, lanes 2-5 show column flow-through fractions, lanes 6-8 show column wash fractions, and lanes 9-14 show fractions from the elution after addition of EDTA.

FIG. 9 shows a Coomassie blue stained SDS-PAGE gel that illustrates the purification of **troponin C**-tagged Ro52 on a troponin I-agarose column in the presence of 8M urea. Lane 1 shows the column load, lanes 2-4 show flow-through fractions, lanes 5-10 show column wash fractions, and lanes 11-15 show fractions of the elution after addition of EDTA.

FIG. 10 shows a comparison between purification of (A) Histagged La antigen (His-La) and (B) **troponin C**-tagged C-terminal truncated La antigen (TnC-La Delta C). Lane 1 shows the column load, lane 2 shows column flow-through, and lane 3 shows the peak fraction of eluted fusion protein. Arrows to the right of the figure illustrate breakdown products or incomplete translation products of the TnC-La Delta C fusion protein.

FIG. 11 shows a Coomassie blue stained SDS-PAGE gel that illustrates thrombin protease cleavage of a **troponin C**-tagged La Delta C molecule (TnC-La Delta C). Lane 1 shows untreated TnC-La Delta C. Lanes 2-5 illustrate thrombin cleavage of the fusion protein with increasing amounts of thrombin. Lane 5 demonstrates complete cleavage of the TnC tag from La Delta C. Lane 1: no thrombin. Lane 2: 0.0125 units thrombin. Lane 3: 0.025 units thrombin. Lane 4: 0.05 units thrombin. Lane 5: 0.1 units thrombin.

L3 ANSWER 2 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2005:274503 USPATFULL

TITLE: 67 human secreted proteins

INVENTOR(S): Ruben, Steven M., Olney, MD, UNITED STATES
 Ferrie, Ann M., Painted Post, NY, UNITED STATES
 Rosen, Craig A., Laytonsville, MD, UNITED STATES
 Florence, Kimberly, Rockville, MD, UNITED STATES
 Carter, Kenneth C., North Potomac, MD, UNITED STATES
 Soppet, Daniel R., Centreville, VA, UNITED STATES
 Yu, Guo-Liang, Berkeley, CA, UNITED STATES
 Florence, Charles, Rockville, MD, UNITED STATES
 Young, Paul E., Gaithersburg, MD, UNITED STATES
 Ni, Jian, Germantown, MD, UNITED STATES
 Endress, Gregory A., Florence, MA, UNITED STATES
 Feng, Ping, Gaithersburg, MD, UNITED STATES
 Janat, Fouad, Westerly, RI, UNITED STATES
 Birse, Charles, North Potomac, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239059	A1	20051027
APPLICATION INFO.:	US 2001-949925	A1	20010912 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 1999-US1621, filed on 27 Jan 1999, PENDING Continuation-in-part of Ser. No. US 1999-363044, filed on 29 Jul 1999, ABANDONED Continuation-in-part of Ser. No. WO 1999-US1621, filed on 27 Jan 1999, PENDING		

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-232150P	20000912 (60)
	US 1998-73170P	19980130 (60)
	US 1998-73167P	19980130 (60)
	US 1998-73165P	19980130 (60)
	US 1998-73164P	19980130 (60)
	US 1998-73162P	19980130 (60)
	US 1998-73161P	19980130 (60)
	US 1998-73160P	19980130 (60)
	US 1998-73159P	19980130 (60)
	US 1998-73170P	19980130 (60)
	US 1998-73167P	19980130 (60)
	US 1998-73165P	19980130 (60)
	US 1998-73164P	19980130 (60)
	US 1998-73162P	19980130 (60)
	US 1998-73161P	19980130 (60)
	US 1998-73160P	19980130 (60)
	US 1998-73159P	19980130 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HUMAN GENOME SCIENCES INC, INTELLECTUAL PROPERTY DEPT., 14200 SHADY GROVE ROAD, ROCKVILLE, MD, 20850, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	21427	

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

L3 ANSWER 3 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2005:233061 USPATFULL
 TITLE: Methods and compositions related to neuronal differentiation
 INVENTOR(S): Majumder, Sadhan, Houston, TX, UNITED STATES
 PATENT ASSIGNEE(S): Board of Regents, The University of Texas System (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2005201995	A1	20050915
APPLICATION INFO.:	US 2005-51668	A1	20050204 (11)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2004-582586P	20040205 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX, 78701, US	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	24 Drawing Page(s)	
LINE COUNT:	4217	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods of the invention use a novel transactivator methodology for manipulation of the molecular mechanisms of cell determination for the production of a cell with a neuronal phenotype. A recombinant transcription factor or transactivator that binds the RE1 promoter element, REST-transactivator, was constructed by replacing the repressor domains of the transcriptional repressor REST with a transcriptional activation domain. The RE1 binding transactivator was

designed to induce or manipulate the neuronal differentiation process.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2005:208895 USPATFULL

TITLE: Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer

INVENTOR(S): Aziz, Natasha, Palo Alto, CA, UNITED STATES
Zlotnik, Albert, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005181375	A1	20050818
APPLICATION INFO.:	US 2004-756149	A1	20040112 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-439058P	20030110 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HOWREY SIMON ARNOLD & WHITE, LLP, C/O M.P. DROSOS, DIRECTOR OF IP ADMINISTRATION, 2941 FAIRVIEW PK, BOX 7, FALLS CHURCH, VA, 22042, US	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
LINE COUNT:	22381	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein are methods and compositions that can be used for diagnosis and treatment of metastatic cancer. Also described herein are methods that can be used to identify modulators of metastatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2005:177230 USPATFULL

TITLE: Luciferase biosensor

INVENTOR(S): Fan, Frank, Madison, WI, UNITED STATES
Lewis, Martin Ken, Madison, WI, UNITED STATES
Shultz, John W., Verona, WI, UNITED STATES
Wood, Keith V., Mt. Horeb, WI, UNITED STATES
Butler, Braeden, Madison, WI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005153310	A1	20050714
APPLICATION INFO.:	US 2004-957433	A1	20041001 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-510187P	20031010 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A., P.O. Box 2938, Minneapolis, MN, 55402, US	
NUMBER OF CLAIMS:	83	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	35 Drawing Page(s)	
LINE COUNT:	4350	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A modified beetle luciferase protein which is an environmentally sensitive reporter protein is provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 6 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2005:87000 USPATFULL

TITLE: Supression of allergic reactions by transdermal administration of allergens conjugated to cholera toxin or fragments thereof

INVENTOR(S): Holmgren, Jan, Vastra Frolunda, SWEDEN
Czerkinsky, Cecil, Nice, FRANCE

PATENT ASSIGNEE(S): Duotol AB, Vastra Frolunda, SWEDEN, S-426 74 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005074462	A1	20050407
APPLICATION INFO.:	US 2004-477909	A1	20040826 (10)
	WO 2002-IB3053		20020523

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293142P	20010523 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	3098	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention discloses the use of the non-toxic cell-binding B subunit of CT (CTB), and holotoxin CT that is devoid of ADP-ribosylating activity, as adjuvants for enhancing transcutaneous immune response to a co-administered protein allergen. It was found that topical administration of CTB to mice induced serum antibody response against itself comparable to those evoked by CT, but was inefficient at promoting systemic antibody responses against an admixed prototype protein allergen. To the contrary co-administration of either CT or CTB with allergen led to vigorous antigen-specific T cell proliferative responses in lymph nodes draining the cutaneous site of administration and at distant systemic sites. Consistent with these observations, it was found that CTB selectively potentiated Th1-driven responses without affecting Th2-dependent responses. Cutaneously applied CT enhanced serum IgE responses to a co-administered allergen, while CTB partially suppressed epicutaneously induced IgE responses to the same allergen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 7 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2005:75214 USPATFULL

TITLE: Polypeptides related to natriuretic peptides and methods of their identification and use

INVENTOR(S): Buechler, Kenneth F., San Diego, CA, UNITED STATES
Fung, Eric Thomas, Mountain View, CA, UNITED STATES
Yip, Tai-Tung, Cupertino, CA, UNITED STATES

PATENT ASSIGNEE(S): CIPHERGEN Biosystems, Inc., Fremont, CA (U.S. corporation)
Biosite, Inc., San Diego, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005064511	A1	20050324
APPLICATION INFO.:	US 2004-827919	A1	20040419 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-419059, filed on 17 Apr 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-466358P	20030428 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO	

CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 85
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Page(s)
LINE COUNT: 3455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the identification and use of polypeptides that bind to antibodies directed to a desired polypeptide of interest. Using natriuretic peptides and their precursors, and in particular BNP, as an example, the present invention describes a number of natriuretic peptides fragments produced in biological samples, most preferably blood-derived samples, that bind to antibodies directed to BNP. Because production of such fragments is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the elapsed time between sample acquisition and the time the sample is analyzed; the type of tissue sample at issue; the storage conditions; the quantity of proteolytic enzymes present; etc., such fragments may be used when both designing an assay for one or more natriuretic peptides, and when performing such an assay, in order to provide an accurate prognostic or diagnostic result.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 8 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2005:74700 USPATFULL
TITLE: Methods and reagents for decreasing clinical reaction to allergy
INVENTOR(S): Caplan, Michael J., Woodbridge, CT, UNITED STATES
Bottomly, Kim H., New Haven, CT, UNITED STATES
Sosin, Howard B., Fairfield, CT, UNITED STATES
Burks, A. Wesley, Chapel Hill, NC, UNITED STATES
Sampson, Hugh A., Larchmont, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005063994	A1	20050324
APPLICATION INFO.:	US 2004-899551	A1	20040726 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-731375, filed on 6 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2002-100303, filed on 18 Mar 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-195035P	20000406 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Choate, Hall & Stewart, Exchange Place, 53 State Street, Boston, MA, 02109	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	38 Drawing Page(s)	
LINE COUNT:	6456	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 9 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2005:3815 USPATFULL
TITLE: Regulation of Acheron expression
INVENTOR(S): Schwartz, Lawrence M., Pelham, MA, UNITED STATES
Wang, Zhaohui, Newton, MA, UNITED STATES
Valavanis, Christos, Athens, GREECE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005002917	A1	20050106
APPLICATION INFO.:	US 2004-841798	A1	20040507 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-468708P	20030507 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	6211	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel apoptosis-associated nucleic acids and polypeptides and methods for use thereof, including methods of treatment of disorders associated with aberrant cellular proliferation, differentiation, or degeneration. Included are methods of enhancing the success of cell transplantation and cell-based genetic therapy procedures.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 10 OF 52 USPATFULL on STN DUPLICATE 2
ACCESSION NUMBER: 2004:12981 USPATFULL
TITLE: Novel 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 molecules and uses therefor
INVENTOR(S): Curtis, Rory A. J., Ashland, MA, UNITED STATES
Logan, Thomas Joseph, Springfield, PA, UNITED STATES
Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Chun, Miyoung, Belmont, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009501	A1	20040115
	US 2004157221	A9	20040812
APPLICATION INFO.:	US 2003-377072	A1	20030227 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-895860, filed on 29 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2000-723806, filed on 28 Nov 2000, PENDING Continuation-in-part of Ser. No. US 2001-843297, filed on 25 Apr 2001, GRANTED, Pat. No. US 6569667 Continuation-in-part of Ser. No. US 2001-861801, filed on 21 May 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-816494, filed on 23 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-888911, filed on 25 Jun 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-908664, filed on 17 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2001-935291, filed on 21 Aug 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215370P	20000629 (60)
	US 2000-187455P	20000307 (60)
	US 2000-199801P	20000426 (60)
	US 2000-205508P	20000519 (60)
	US 2000-213688P	20000623 (60)
	US 2000-218675P	20000717 (60)
	US 2000-250932P	20001130 (60)
	US 2000-226504P	20000821 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Jean M. Silveri, 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	16123	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The invention provides isolated nucleic acids molecules, designated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 and 49933 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 gene has been introduced or disrupted. The invention still further provides isolated 25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 proteins, fusion proteins, antigenic peptides and anti-25869, 25934, 26335, 50365, 21117, 38692, 46508, 16816, 16839, 49937, 49931 or 49933 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:905784 CAPLUS
 DOCUMENT NUMBER: 141:376819
 TITLE: **Affinity purification** system using troponin molecules as affinity ligands
 INVENTOR(S): Moeckli, Randolph A.; Chadwick, Christopher C.
 PATENT ASSIGNEE(S): Aristex, USA
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092214	A2	20041028	WO 2004-US10887	20040407
WO 2004092214	A3	20041118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG US 2005043510 A1 20050224 US 2004-820998 20040407 PRIORITY APPLN. INFO.: US 2003-462483P P 20030410 AB This invention pertains to the use of a novel set of tags for the				

immobilization and/or purification of proteins or other biol. or organic mols.
The invention provides **troponin C**, **troponin C** binding peptide, and troponin I, or active fragments or analogs thereof as convenient tags and affinity ligands for immobilizing, attaching, or purifying proteins or other mols. Methods for producing troponin-tagged mols., such as recombinant fusion proteins, are described. Methods for preparing a troponin affinity **matrix** that is capable of specifically binding its cognate ligand in the presence of calcium, and methods for using such a **matrix** to purify troponin-tagged mols. are also described.

L3 ANSWER 12 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:327379 USPATFULL
TITLE: 32544, Novel human phospholipase C and uses thereof
INVENTOR(S): Meyers, Rachel, Newton, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004259199	A1	20041223
APPLICATION INFO.:	US 2004-784089	A1	20040220 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-927112, filed on 10 Aug 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-246808P	20001108 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLENNIUM PHARMACEUTICALS, INC., 40 Landsdowne Street, CAMBRIDGE, MA, 02139	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	5297	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32544 nucleic acid molecules, which encode novel phospholipase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32544 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32544 gene has been introduced or disrupted. The invention still further provides isolated 32544 proteins, fusion proteins, antigenic peptides and anti-32544 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 13 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:280221 USPATFULL
TITLE: Novel nucleic acids and polypeptides
INVENTOR(S): Tang, Y. Tom, San Jose, CA, UNITED STATES
Wang, Zhiwei, Sunnyvale, CA, UNITED STATES
Weng, Gezhi, Piedmont, CA, UNITED STATES
Boyle, Bryan J., San Francisco, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004219521	A1	20041104
APPLICATION INFO.:	US 2002-128558	A1	20020422 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2000-US35017, filed on 22 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-552317, filed on 25 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed		

on 21 Jan 2000, PENDING Continuation-in-part of Ser.
No. WO 2001-US2623, filed on 25 Jan 2001, PENDING
Continuation-in-part of Ser. No. US 2000-491404, filed
on 25 Jan 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2000-US35017	20001222
	WO 2001-US2623	20010125
	WO 2001-US3800	20010205
	WO 2001-US4927	20010226
	WO 2001-US4941	20010305
	WO 2001-US8631	20010330
	WO 2001-US8656	20010418
	US 2001-339453P	20011211 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Luisa Bigornia, HYSEQ, INC., 670 Almanor Avenue,
Sunnyvale, CA, 94085

NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
LINE COUNT: 13159

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel nucleic acids, novel polypeptide
sequences encoded by these nucleic acids and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 14 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:239700 USPATFULL
TITLE: Epitope mapping using nuclear magnetic resonance
INVENTOR(S): Heavner, George A., Malvern, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004185506	A1	20040923
APPLICATION INFO.:	US 2003-393926	A1	20030321 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
LINE COUNT:	2213		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to methods for mapping or otherwise identifying
the amino acid sequence and conformation of a portion of a protein that
is involved in ligand binding. This invention finds utility in the
process of elucidating the amino acid sequence and conformation of an
epitope of, for example, an antigen or an antibody that binds to the
antigen.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 15 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:228528 USPATFULL
TITLE: Methods and compositions for measuring biologically
active natriuretic peptides and for improving their
therapeutic potential
INVENTOR(S): Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED
STATES
Whittaker, Michael, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): Biosite Incorporated (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004176914	A1	20040909
APPLICATION INFO.:	US 2003-645874	A1	20030820 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2003-419059, filed on 17 Apr 2003, PENDING Continuation-in-part of Ser. No. US 2001-835298, filed on 13 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2002-139086, filed on 4 May 2002, PENDING Continuation-in-part of Ser. No. WO 2002-US26604, filed on 20 Aug 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-288871P	20010504 (60)
	US 2001-315642P	20010828 (60)
	US 2001-313775P	20010820 (60)
	US 2001-334964P	20011130 (60)
	US 2002-346485P	20020102 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278

NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
LINE COUNT: 2809

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes compositions and methods designed to determine the presence or amount of biologically active natriuretic peptides, or their fragments, in a sample. The degradation of natriuretic peptides is an ongoing process that may be a function of, inter alia, the elapsed time between onset of an event triggering natriuretic peptide release into the tissues and the time the sample is obtained or analyzed; the quantity of proteolytic enzymes present; etc. This degradation can produce circulating amounts of natriuretic peptides having reduced or lost biological function. The present invention provides, inter alia, assays designed to accurately measure biologically active natriuretic peptides, and compositions to inhibit a previously unknown pathway for degradation of natriuretic peptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 16 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2004:196865 USPATFULL
TITLE: Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media
INVENTOR(S): Lee, Chichang, Norristown, PA, UNITED STATES
Moore, Gordon, Wayne, PA, UNITED STATES
Savino, Edward, Downingtown, PA, UNITED STATES
Shi, Xiaomei, Collegeville, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004152170	A1	20040805
APPLICATION INFO.:	US 2003-727432	A1	20031204 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-316308, filed on 11 Dec 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-339428P	20011214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHILIP S. JOHNSON, JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Page(s)	
LINE COUNT:	2600	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to clonal myeloma cell lines that have the ability to grow continuously in chemically defined media. The present invention also relates to the production of proteins in clonal myeloma

cell lines and any cell lines derived therefrom. The present invention further relates to methods for identifying cell lines capable of growing in chemically defined media.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 17 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:101093 USPATFULL

TITLE: Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer

INVENTOR(S): Mack, David H., Menlo Park, CA, UNITED STATES

Aziz, Natasha, Palo Alto, CA, UNITED STATES

PATENT ASSIGNEE(S): Eos Biotechnology, Inc., South San Francisco, CA, UNITED STATES, 94080-7019 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004076955	A1	20040422
APPLICATION INFO.:	US 2002-188832	A1	20020702 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-372246P	20020412 (60)
	US 2001-350666P	20011113 (60)
	US 2001-343705P	20011108 (60)
	US 2001-310099P	20010803 (60)
	US 2001-302814P	20010703 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HOWREY SIMON ARNOLD & WHITE, LLP, BOX 34, 301 RAVENSWOOD AVE., MENLO PARK, CA, 94025

NUMBER OF CLAIMS: 20

EXEMPLARY CLAIM: 1

LINE COUNT: 27357

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Described herein are genes whose expression are up-regulated or down-regulated in bladder cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant bladder cancer cells. Related methods and compositions that can be used for diagnosis, prognosis, or treatment of bladder cancer are disclosed. Also described herein are methods that can be used to identify modulators of bladder cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 18 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:76577 USPATFULL

TITLE: Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor

INVENTOR(S): Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES

Hunter, John Joseph, Somerville, MA, UNITED STATES

Meyers, Rachel E., Newton, MA, UNITED STATES

Rudolph-Owen, Laura A., Medford, MA, UNITED STATES

Curtis, Rory A. J., Framingham, MA, UNITED STATES

Olandt, Peter J., Newton, MA, UNITED STATES

Tsai, Fong-Ying, Newton, MA, UNITED STATES

Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES

Chun, Miyoung, Belmont, MA, UNITED STATES

Williamson, Mark J., Saugus, MA, UNITED STATES

Silos-Santiago, Inmaculada, Del Mar, CA, UNITED STATES

Bandaru, Rajasekhar, Watertown, MA, UNITED STATES

PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004058355 A1 20040325
 APPLICATION INFO.: US 2003-423543 A1 20030425 (10)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2002-278036, filed
 on 22 Oct 2002, PENDING Continuation of Ser. No. US
 2000-711216, filed on 9 Nov 2000, ABANDONED
 Continuation-in-part of Ser. No. US 2001-12055, filed
 on 13 Nov 2001, PENDING Continuation-in-part of Ser.
 No. US 2001-3690, filed on 15 Nov 2001, PENDING
 Continuation-in-part of Ser. No. US 2001-797039, filed
 on 28 Feb 2001, PENDING Continuation-in-part of Ser.
 No. US 2002-217168, filed on 12 Aug 2002, PENDING
 Continuation-in-part of Ser. No. US 2001-929218, filed
 on 14 Aug 2001, ABANDONED Continuation-in-part of Ser.
 No. US 2001-963159, filed on 25 Sep 2001, ABANDONED
 Continuation-in-part of Ser. No. US 2002-121911, filed
 on 12 Apr 2002, GRANTED, Pat. No. US 6607892 Division
 of Ser. No. US 1999-412210, filed on 5 Oct 1999,
 GRANTED, Pat. No. US 6403358 Continuation-in-part of
 Ser. No. US 2002-105989, filed on 25 Mar 2002, PENDING
 Continuation of Ser. No. US 1999-392189, filed on 9 Sep
 1999, ABANDONED Continuation-in-part of Ser. No. US
 2003-336153, filed on 3 Jan 2003, PENDING Continuation
 of Ser. No. US 2001-845044, filed on 27 Apr 2001,
 ABANDONED Continuation-in-part of Ser. No. US
 2001-928531, filed on 13 Aug 2001, ABANDONED
 Continuation-in-part of Ser. No. US 2001-920346, filed
 on 31 Jul 2001, PENDING Continuation-in-part of Ser.
 No. US 2001-8016, filed on 8 Nov 2001, PENDING
 Continuation-in-part of Ser. No. US 2001-909743, filed
 on 20 Jul 2001, PENDING Division of Ser. No. US
 1999-448076, filed on 23 Nov 1999, GRANTED, Pat. No. US
 6300092 Continuation-in-part of Ser. No. US
 1999-276400, filed on 25 Mar 1999, GRANTED, Pat. No. US
 6140056 Continuation-in-part of Ser. No. US
 2003-336489, filed on 2 Jan 2003, PENDING Continuation
 of Ser. No. US 2000-608921, filed on 30 Jun 2000,
 ABANDONED Continuation-in-part of Ser. No. US
 1998-163821, filed on 30 Sep 1998, ABANDONED
 Continuation-in-part of Ser. No. US 2002-60763, filed
 on 30 Jan 2002, ABANDONED Continuation of Ser. No. US
 1999-365162, filed on 30 Jul 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-205447P	20000519 (60)
	US 2000-248325P	20001114 (60)
	US 2000-248893P	20001115 (60)
	US 2000-186061P	20000229 (60)
	US 2001-312539P	20010815 (60)
	US 2000-257511P	20001222 (60)
	US 2000-234922P	20000925 (60)
	US 2000-200688P	20000428 (60)
	US 2000-235035P	20000925 (60)
	US 2000-221925P	20000731 (60)
	US 2001-260166P	20010105 (60)
	US 2000-246669P	20001108 (60)
	US 1999-117580P	19990127 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Millennium Pharmaceuticals, Inc., 75 Sidney Street,
 Cambridge, MA, 02139

NUMBER OF CLAIMS: 19
 EXEMPLARY CLAIM: 1
 LINE COUNT: 14751

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated
 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529,

26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 and 593 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 gene has been introduced or disrupted. The invention still further provides isolated 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 proteins, fusion proteins, antigenic peptides and anti-21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, h1983, m1983, 38555 or 593 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 19 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:63731 USPATFULL
 TITLE: Novel nucleic acids and secreted polypeptides
 INVENTOR(S): Tang, Y. Tom, San Jose, CA, UNITED STATES
 Yang, Yonghong, San Jose, CA, UNITED STATES
 Weng, Gezhi, Piedmont, CA, UNITED STATES
 Zhang, Jie, Campbell, CA, UNITED STATES
 Ren, Feiyan, Cupertino, CA, UNITED STATES
 Xue, Aidong, Sunnyvale, CA, UNITED STATES
 Wang, Jian-Rui, Cupertino, CA, UNITED STATES
 Wehrman, Tom, Stanford, CA, UNITED STATES
 Ghosh, Malabika J., Sunnyvale, CA, UNITED STATES
 Wang, Dunrui, Poway, CA, UNITED STATES
 Zhao, Qing A., San Jose, CA, UNITED STATES
 Wang, Zhiwei, Sunnyvale, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048249	A1	20040311
APPLICATION INFO.:	US 2002-112944	A1	20020328 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING Continuation-in-part of Ser. No. US 2000-491404, filed on 25 Jan 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-496914, filed on 3 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-515126, filed on 28 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-519705, filed on 7 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-540217, filed on 31 Mar 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-552929, filed on 18 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-577408, filed on 18 May 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-306971P	20010721 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Luisa Biogornia, HYSEQ, INC., 670 Almanor Avenue, Sunnyvale, CA, 94085	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
LINE COUNT:	23809	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 20 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:50848 USPATFULL

TITLE: 125 human secreted proteins

INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Feng, Ping, Germantown, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik, Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Kyaw, Hla, Boonsboro, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004038277	A1	20040226
APPLICATION INFO.:	US 2003-621401	A1	20030718 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-974879, filed on 12 Oct 2001, PENDING Continuation-in-part of Ser. No. US 2001-818683, filed on 28 Mar 2001, PENDING Continuation of Ser. No. US 1999-305736, filed on 5 May 1999, PENDING Continuation-in-part of Ser. No. WO 1998-US23435, filed on 4 Nov 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-239893P	20001013 (60)
	US 1997-64911P	19971107 (60)
	US 1997-64912P	19971107 (60)
	US 1997-64983P	19971107 (60)
	US 1997-64900P	19971107 (60)
	US 1997-64988P	19971107 (60)
	US 1997-64987P	19971107 (60)
	US 1997-64908P	19971107 (60)
	US 1997-64984P	19971107 (60)
	US 1997-64985P	19971107 (60)
	US 1997-66094P	19971117 (60)
	US 1997-66100P	19971117 (60)
	US 1997-66089P	19971117 (60)
	US 1997-66095P	19971117 (60)
	US 1997-66090P	19971117 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 38927

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 21 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:44517 USPATFULL
TITLE: Novel 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 molecules and uses therefor
INVENTOR(S): Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark J., Saugus, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
MacBeth, Kyle J., Boston, MA, UNITED STATES
Hunter, John Joseph, Somerville, MA, UNITED STATES
Rudolph-Owen, Laura A., Medford, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Tsai, Fong-Ying, Newton, MA, UNITED STATES
PATENT ASSIGNEE(S): Millennium Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004033509	A1	20040219
APPLICATION INFO.:	US 2003-377097	A1	20030228 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-910150, filed on 18 Jul 2001, ABANDONED Continuation-in-part of Ser. No. US 2002-251507, filed on 20 Sep 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-219028P	20000718 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLENNIUM PHARMACEUTICALS, INC., 75 Sidney Street, Cambridge, MA, 02139	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	15960	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 and 32252 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 gene has been introduced or disrupted. The invention still further provides isolated 13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 proteins, fusion proteins, antigenic peptides and anti-13237, 18480, 2245, 16228, 7677, 26320, 46619, 33166, 16836, 46867, 21617, 55562, 39228, 62088, 46745, 23155, 21657, 42755, 32229, 22325, 46863 or 32252 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 22 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:44514 USPATFULL
TITLE: Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
INVENTOR(S): Farrelly, Dennis, Monmouth Junction, NJ, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES

Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Wu, Shujian, Langhorne, PA, UNITED STATES
Bassolino, Donna A., Hamilton, NJ, UNITED STATES
Krystek, Stanley R., Ringoes, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004033506	A1	20040219
APPLICATION INFO.:	US 2002-308128	A1	20021202 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-334904P	20011130 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	37 Drawing Page(s)	
LINE COUNT:	28557	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding Mitochondrial GPAT, Microsomal GPAT_hlog1, Microsomal GPAT_hlog2, Microsomal GPAT_hlog3, and/or Microsomal GPAT_hlog3_v1 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Mitochondrial GPAT, Microsomal GPAT_hlog1, Microsomal GPAT_hlog2, Microsomal GPAT_hlog3, and/or Microsomal GPAT_hlog3_v1 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 23 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:18791 USPATFULL
TITLE: Polynucleotide encoding a novel cysteine protease of the calpain superfamily, Protease-42
INVENTOR(S): Duclos, Franck, Washington Crossing, PA, UNITED STATES
Chen, Jian, Princeton, NJ, UNITED STATES
Feder, John N., Belle Mead, NJ, UNITED STATES
Nayeem, Akbar, Newtown, PA, UNITED STATES
Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004014093	A1	20040122
APPLICATION INFO.:	US 2003-390585	A1	20030314 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-364941P	20020314 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	19269	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding Protease-42 polypeptides, fragments and homologues thereof. Also

provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel Protease-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 24 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:12957 USPATFULL

TITLE: Methods for producing libraries of expressible gene sequences

INVENTOR(S): Fernandez, Joseph M., Carlsbad, CA, UNITED STATES
Heyman, John A., Rixensart, BELGIUM
Hoeffler, James P., Anchorage, AK, UNITED STATES
Marks-Hull, Heather L., Oceanside, CA, UNITED STATES
Sindici, Michelle L., San Diego, CA, UNITED STATES

PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009477	A1	20040115
APPLICATION INFO.:	US 2001-990091	A1	20011121 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-843281, filed on 25 Apr 2001, ABANDONED Continuation of Ser. No. US 647651, ABANDONED A 371 of International Ser. No. WO 1999-US7270, filed on 2 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-54936, filed on 3 Apr 1998, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-7270	19990402
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LISA A. HAILE, Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	4754	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention comprises a method for producing libraries of expressible gene sequences. The method of the invention allows for the simultaneous manipulation of multiple gene sequences and thus allows libraries to be created in an efficient and high throughput manner. The expression vectors containing verified gene sequences can be used to transfect cells for the production of recombinant proteins. The invention further comprises libraries of expressible gene sequences produced using the method of the invention and expression vectors used in the construction of said libraries.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 25 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:7304 USPATFULL

TITLE: Method of identifying toxic agents using differential gene expression

INVENTOR(S): Gould-Rothberg, Bonnie, Guilford, CT, UNITED STATES
Dipippo, Vincent, East Haven, CT, UNITED STATES
Daniels, Kellye K., Kirkland, WA, UNITED STATES

PATENT ASSIGNEE(S): CuraGen Corporation, New Haven, CT (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004005537 A1 20040108
 APPLICATION INFO.: US 2003-428681 A1 20030502 (10)
 RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-791945, filed on 22
 Feb 2001, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-184017P	20000222 (60)
	US 2000-213027P	20000621 (60)
	US 2000-239535P	20001010 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MINTZ, LEVIN, COHN, FERRIS, GLOVSKY, AND POPEO, P.C., ONE FINANCIAL CENTER, BOSTON, MA, 02111	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
LINE COUNT:	5639	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are methods of identifying toxic agents, e.g., cardiotoxic agents, using differential gene expression. Also disclosed are novel nucleic acid sequences whose expression is differentially regulated by serotonin modulating agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 26 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2004:2561 USPATFULL

TITLE: Proteins, polynucleotides encoding them and methods of using the same

INVENTOR(S): Pena, Carol E. A., New Haven, CT, UNITED STATES
 Shimkets, Richard A., Guilford, CT, UNITED STATES
 Li, Li, Branford, CT, UNITED STATES
 Shenoy, Suresh G., Branford, CT, UNITED STATES
 Kekuda, Ramesh, Norwalk, CT, UNITED STATES
 Spytek, Kimberly A., New Haven, CT, UNITED STATES
 Vernet, Corine A.M., Branford, CT, UNITED STATES
 Malyankar, Uriel M., Branford, CT, UNITED STATES
 Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
 Gusev, Vladimir Y., Madison, CT, UNITED STATES
 Casman, Stacie J., North Haven, CT, UNITED STATES
 Boldog, Ferenc L., North Haven, CT, UNITED STATES
 Furtak, Katarzyna, Ansonia, CT, UNITED STATES
 Tchernev, Velizar T., Branford, CT, UNITED STATES
 Patturajan, Meera, Branford, CT, UNITED STATES
 Gangolli, Esha A., Madison, CT, UNITED STATES
 Padigar, Muralidhara, Branford, CT, UNITED STATES
 Liu, Xiaohong, Branford, CT, UNITED STATES
 Baumgartner, Jason C., New Haven, CT, UNITED STATES
 Gerlach, Valerie, Branford, CT, UNITED STATES
 Spaderna, Steven K., Berlin, CT, UNITED STATES
 Zerhusen, Bryan D., Branford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004002584	A1	20040101
APPLICATION INFO.:	US 2002-80334	A1	20020221 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-270523P	20010221 (60)
	US 2001-322712P	20010917 (60)
	US 2001-311980P	20010813 (60)
	US 2001-330307P	20011018 (60)
	US 2001-278796P	20010326 (60)
	US 2001-281521P	20010404 (60)
	US 2001-276677P	20010316 (60)
	US 2001-311595P	20010810 (60)

US 2001-270220P 20010221 (60)
US 2001-274295P 20010308 (60)
US 2001-318526P 20010910 (60)
US 2001-286548P 20010425 (60)
US 2001-291765P 20010517 (60)
US 2001-270797P 20010223 (60)
US 2001-276400P 20010316 (60)
US 2001-270810P 20010223 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ivor R. Elrifi, Mintz, Levin, Cohn, Ferris,, Glovsky
and Popeo, P.C., One Financial Center, Boston, MA,
02111
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 20544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are nucleic acid sequences that encode novel
polypeptides. Also disclosed are polypeptides encoded by these nucleic
acid sequences, and antibodies, which immunospecifically-bind to the
polypeptide, as well as derivatives, variants, mutants, or fragments of
the aforementioned polypeptide, polynucleotide, or antibody. The
invention further discloses therapeutic, diagnostic and research methods
for diagnosis, treatment, and prevention of disorders involving any one
of these novel human nucleic acids and proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 27 OF 52 USPATFULL on STN DUPLICATE 3
ACCESSION NUMBER: 2003:159258 USPATFULL
TITLE: Genes expressed in treated human C3A liver cell
cultures
INVENTOR(S): Kaser, Matthew R., Castro Valley, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003108871	A1	20030612
	US 6727066	B2	20040427
APPLICATION INFO.:	US 2001-919039	A1	20010730 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-222113P	20000728 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE GENOMICS INC., 3160 Porter Drive, Palo Alto, CA, 94304	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4316	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a composition comprising a plurality of
cDNAs which are differentially expressed in treated human C3A liver cell
cultures and which may be used entirely or in part to diagnose, to
stage, to treat, or to monitor the progression or treatment of liver
disorders such as hyperlipidemia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 28 OF 52 USPATFULL on STN
ACCESSION NUMBER: 2003:312137 USPATFULL
TITLE: Polypeptides related to natriuretic peptides and
methods of their identification and use
INVENTOR(S): Buechler, Kenneth F., Rancho Santa Fe, CA, UNITED
STATES
PATENT ASSIGNEE(S): Biosite Incorporated (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003219734 A1 20031127
 APPLICATION INFO.: US 2003-419059 A1 20030417 (10)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-835298, filed
 on 13 Apr 2001, PENDING Continuation-in-part of Ser.
 No. WO 2002-US26604, filed on 20 Aug 2002, PENDING
 Continuation-in-part of Ser. No. US 2002-139086, filed
 on 4 May 2002, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-313775P	20010820 (60)
	US 2001-334964P	20011130 (60)
	US 2002-346485P	20020102 (60)
	US 2001-288871P	20010504 (60)
	US 2001-315642P	20010828 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA,
 92138-0278

NUMBER OF CLAIMS: 55
 EXEMPLARY CLAIM: 1
 LINE COUNT: 1949

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the identification and use of
 polypeptides that bind to antibodies directed to a desired polypeptide
 of interest. Using natriuretic peptides and their precursors, and in
 particular BNP, as an example, the present invention describes a number
 of natriuretic peptides fragments produced in biological samples, most
 preferably blood-derived samples, that bind to antibodies directed to
 BNP. Because production of such fragments is an ongoing process that may
 be a function of, inter alia, the elapsed time between onset of an event
 triggering natriuretic peptide release into the tissues and the time the
 sample is obtained or analyzed; the elapsed time between sample
 acquisition and the time the sample is analyzed; the type of tissue
 sample at issue; the storage conditions; the quantity of proteolytic
 enzymes present; etc., such fragments may be used when both designing an
 assay for one or more natriuretic peptides, and when performing such an
 assay, in order to provide an accurate prognostic or diagnostic result.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 29 OF 52 USPATFULL on STN
 ACCESSION NUMBER: 2003:299857 USPATFULL
 TITLE: Pseudo-antibody constructs
 INVENTOR(S): Heavner, George A., Malvern, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003211078	A1	20031113
APPLICATION INFO.:	US 2002-309722	A1	20021204 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-336707P	20011207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	67	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2660	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel pharmaceutically useful compositions
 that bind to a biological molecule, having improved circulatory
 half-life, increased avidity, increased affinity, or multifunctionality,
 and methods of use thereof. The present invention provides a

pseudo-antibody comprising an organic moiety covalently coupled to at least two target-binding moieties, wherein the target-binding moieties are selected from the group consisting of a protein, a peptide, a peptidomimetic, and a non-peptide molecule that binds to a specific targeted biological molecule. The pseudo-antibody of the present invention may affect a specific ligand in vitro, in situ and/or in vivo. The pseudo-antibodies of the present invention can be used to measure or effect in an cell, tissue, organ or animal (including humans), to diagnose, monitor, modulate, treat, alleviate, help prevent the incidence of, or reduce the symptoms of, at least one condition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 30 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:271453 USPATFULL
 TITLE: Regulation of human plc delta-1
 INVENTOR(S): Xiao, Yonghong, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003191060	A1	20031009
APPLICATION INFO.:	US 2002-276339	A1	20021127 (10)
	WO 2001-EP6087		20010529
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001		
NUMBER OF CLAIMS:	75		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Page(s)		
LINE COUNT:	3193		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Reagents which regulate human PLC delta-1 activity and reagents which bind to human PLC delta-1 gene products can be used, inter alia, to treat COPD, congestive heart failure, hypertension, and cancer, and a variety of conditions in which signal transduction is impaired.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 31 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:251849 USPATFULL
 TITLE: Stabilization of cardiac troponin I subunits and complexes
 INVENTOR(S): Dave, Kirti I., Thousand Oaks, CA, UNITED STATES
 Fernandez, Brian Robert, Tarzana, CA, UNITED STATES
 PATENT ASSIGNEE(S): Medical Analysis Systems, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003176638	A1	20030918
APPLICATION INFO.:	US 2003-358070	A1	20030204 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-845091, filed on 27 Apr 2001, GRANTED, Pat. No. US 6538104		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	CHRISTINE, PARKER & HALE, LLP, P.O. BOX 7068, PASADENA, CA, 91109-7068		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1037		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for preparing, and compositions comprising, stabilized protein-polymer conjugates. More particularly, the present invention relates to the stabilization of individual and complexed subunits of multisubunit protein complexes by conjugation to polymers. Such conjugation acts to stabilize the specific subunit complexes in their native conformation in liquid medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 32 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:237990 USPATFULL

TITLE: Clonal myeloma cell lines useful for manufacturing proteins in chemically defined media

INVENTOR(S): Lee, ChiChang, Norristown, PA, UNITED STATES
Savino, Edward, UNITED STATES
Moore, Gordon, Wayne, PA, UNITED STATES
Ly, Celia, Lancaster, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166147	A1	20030904
APPLICATION INFO.:	US 2002-316311	A1	20021211 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-339429P	20011214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	2532	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to clonal myeloma cell lines that have the ability to grow continuously in chemically defined media. The present invention also relates to the production of proteins in clonal myeloma cell lines and any cell lines derived therefrom. The present invention further relates to methods for identifying cell lines capable of growing in chemically defined media. The present invention also relates to business methods where customers are provided with the cells, cell lines, and cell cultures of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 33 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:237989 USPATFULL

TITLE: Myeloma cell line useful for manufacturing recombinant proteins in chemically defined media

INVENTOR(S): Lee, ChiChang, Norristown, PA, UNITED STATES
Savino, Edward, Malvern, PA, UNITED STATES
Moore, Gordon, Wayne, PA, UNITED STATES
Ly, Celia, Lancaster, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166146	A1	20030904
APPLICATION INFO.:	US 2002-316308	A1	20021211 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-339428P	20011214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	2558	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a novel myeloma cell line, designated C463A, and derivatives of C463A, which have the ability to grow continuously in chemically defined media. The present invention also

relates to the production of proteins in cell line C463A and any cell line derived therefrom. The present invention further relates to methods for identifying cell lines capable of growing in chemically defined media. The present invention also relates to business methods where customers are provided with the cells, cell lines, and cell cultures of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 34 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:213657 USPATFULL
TITLE: Expression profiles and methods of use
INVENTOR(S): Wan, Jackson Shek-Lam, San Diego, CA, UNITED STATES
Wang, Yixin, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003148295	A1	20030807
APPLICATION INFO.:	US 2002-101510	A1	20020320 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-276947P	20010320 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PRESTON GATES ELLIS & ROUVELAS MEEDS LLP, 1735 NEW YORK AVENUE, NW, SUITE 500, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	90	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	47 Drawing Page(s)	
LINE COUNT:	7505	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to gene expression profiles, algorithms to generate gene expression profiles, microarrays comprising nucleic acid sequences representing gene expression profiles, methods of using gene expression profiles and microarrays, and business methods directed to the use of gene expression profiles, microarrays, and algorithms. The present invention further relates to protein expression profiles, algorithms to generate protein expression profiles, microarrays comprising protein-capture agents that bind proteins comprising protein expression profiles, methods of using protein expression profiles and microarrays, and business methods directed to the use of protein expression profiles, microarrays, and algorithms.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 35 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:194491 USPATFULL
TITLE: Libraries of expressible gene sequences
INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES
Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003134302	A1	20030717
APPLICATION INFO.:	US 2002-210985	A1	20020801 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-3021, filed on 14 Nov 2001, PENDING Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)
DOCUMENT TYPE:	Utility	

FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE &
 FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San
 Diego, CA, 92121-2133
 NUMBER OF CLAIMS: 40
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 1 Drawing Page(s)
 LINE COUNT: 9810

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as **affinity purification** tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 36 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:166515 USPATFULL
 TITLE: Polynucleotide encoding a novel cysteine protease of
 the calpain superfamily, CAN-12, and variants thereof
 INVENTOR(S): Chen, Jian, Princeton, NJ, UNITED STATES
 Feder, John N., Belle Mead, NJ, UNITED STATES
 Nelson, Thomas C., Lawrenceville, NJ, UNITED STATES
 Seiler, Steven, Pennington, NJ, UNITED STATES
 Vaz, Roy J., North Branch, NJ, UNITED STATES
 Duclos, Franck, Washington Crossing, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003114373	A1	20030619
APPLICATION INFO.:	US 2002-116519	A1	20020403 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-281253P	20010403 (60)
	US 2001-288768P	20010504 (60)
	US 2001-296180P	20010606 (60)
	US 2001-300620P	20010625 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT
 DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000

NUMBER OF CLAIMS: 23
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 27 Drawing Page(s)
 LINE COUNT: 30149

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides novel polynucleotides encoding CAN-12 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants of CAN-12 polypeptides, CAN-12v1 and CAN-12v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel CAN-12, CAN-12v1, and CAN-12v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, particularly neuro- and musculo-degenerative conditions. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 37 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:106252 USPATFULL
TITLE: Libraries of expressible gene sequences
INVENTOR(S): Fernandez, Joseph Manuel, Carlsbad, CA, UNITED STATES
Heyman, John Alastair, Cardiff-by-the-Sea, CA, UNITED STATES
Hoeffler, James Paul, Carlsbad, CA, UNITED STATES
PATENT ASSIGNEE(S): INVITROGEN CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073163	A1	20030417
APPLICATION INFO.:	US 2001-3021	A1	20011114 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-285386, filed on 2 Apr 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96981P	19980818 (60)
	US 1998-80626P	19980403 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Lisa A. Haile, J.D., Ph.D., GRAY CARY WARE & FREIDENRICH LLP, Suite 1100, 4365 Executive Drive, San Diego, CA, 92121-2133	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	9813	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The invention described herein comprises libraries of expressible gene sequences. Such gene sequences are contained on plasmid vectors designed to endow the expressed proteins with a number of useful features such as **affinity purification** tags, epitope tags, and the like. The expression vectors containing such gene sequences can be used to transfect cells for the production of recombinant proteins. A further aspect of the invention comprises methods of identifying binding partners for the products of such expressible gene sequences.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 38 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:93796 USPATFULL
TITLE: Genes expressed in lung cancer
INVENTOR(S): Lasek, Amy W., Oakland, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003065157	A1	20030403
APPLICATION INFO.:	US 2002-116802	A1	20020404 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-281593P	20010404 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE GENOMICS, INC., 3160 PORTER DRIVE, PALO ALTO, CA, 94304	
NUMBER OF CLAIMS:	28	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4232	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in a respiratory disorder and which may be used in their entirety or in part to diagnose, to stage, to treat, or to monitor the treatment of a subject with a respiratory disorder.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 39 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:79303 USPATFULL
TITLE: 12 human secreted proteins
INVENTOR(S): Ni, Jian, Germantown, MD, UNITED STATES
Young, Paul E., Gaithersburg, MD, UNITED STATES
Kenny, Joseph J., Damascus, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Greene, John M., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Liu, Ding, Gaithersburg, MD, UNITED STATES
Crocker, Paul R., Dundee, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055231	A1	20030320
APPLICATION INFO.:	US 2001-984130	A1	20011029 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-836353, filed on 18 Apr 2001, PENDING Continuation-in-part of Ser. No. WO 1999-US25031, filed on 27 Oct 1999, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-243792P	20001030 (60)
	US 2000-198407P	20000419 (60)
	US 1998-105971P	19981028 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 67 Drawing Page(s)
LINE COUNT: 31982

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to 12 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 40 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2003:38356 USPATFULL
TITLE: 125 human secreted proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Feng, Ping, Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ni, Jian, Germantown, MD, UNITED STATES
Wei, Ying-Fei, Berkeley, CA, UNITED STATES
Soppet, Daniel R., Centreville, VA, UNITED STATES
Moore, Paul A., Germantown, MD, UNITED STATES
Kyaw, Hla, Frederick, MD, UNITED STATES
LaFleur, David W., Washington, DC, UNITED STATES
Shi, Yanggu, Gaithersburg, MD, UNITED STATES
Janat, Fouad, Westerly, RI, UNITED STATES
Endress, Gregory A., Florence, MA, UNITED STATES
Carter, Kenneth C., North Potomac, MD, UNITED STATES
Birse, Charles E., North Potomac, MD, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003028003 A1 20030206
 APPLICATION INFO.: US 2001-974879 A1 20011012 (9)
 RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2001-818683, filed
 on 28 Mar 2001, PENDING Continuation of Ser. No. US
 1999-305736, filed on 5 May 1999, PENDING
 Continuation-in-part of Ser. No. WO 1998-US23435, filed
 on 4 Nov 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-239893P	20001013 (60)
	US 1997-64911P	19971107 (60)
	US 1997-64912P	19971107 (60)
	US 1997-64983P	19971107 (60)
	US 1997-64900P	19971107 (60)
	US 1997-64988P	19971107 (60)
	US 1997-64987P	19971107 (60)
	US 1997-64908P	19971107 (60)
	US 1997-64984P	19971107 (60)
	US 1997-64985P	19971107 (60)
	US 1997-66094P	19971117 (60)
	US 1997-66100P	19971117 (60)
	US 1997-66089P	19971117 (60)
	US 1997-66095P	19971117 (60)
	US 1997-66090P	19971117 (60)

DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,
 ROCKVILLE, MD, 20850

NUMBER OF CLAIMS: 23
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 3 Drawing Page(s)
 LINE COUNT: 36277

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel human secreted proteins and
 isolated nucleic acids containing the coding regions of the genes
 encoding such proteins. Also provided are vectors, host cells,
 antibodies, and recombinant methods for producing human secreted
 proteins. The invention further relates to diagnostic and therapeutic
 methods useful for diagnosing and treating diseases, disorders, and/or
 conditions related to these novel human secreted proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 41 OF 52 USPATFULL on STN DUPLICATE 4
 ACCESSION NUMBER: 2002:337922 USPATFULL
 TITLE: Stabilization of cardiac troponin I subunits and
 complexes
 INVENTOR(S): Dave, Kirti I., Thousand Oaks, CA, UNITED STATES
 Fernandez, Brian Robert, Tarzana, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002193287	A1	20021219
	US 6538104	B2	20030325
APPLICATION INFO.:	US 2001-845091	A1	20010427 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	CHRISTIE, PARKER & HALE, LLP, 350 WEST COLORADO BOULEVARD, SUITE 500, PASADENA, CA, 91105		
NUMBER OF CLAIMS:	32		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1088		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for preparing, and compositions
 comprising, stabilized protein-polymer conjugates. More particularly,
 the present invention relates to the stabilization of individual and

complexed subunits of multisubunit protein complexes by conjugation to polymers. Such conjugation acts to stabilize the specific subunit complexes in their native conformation in liquid medium.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 42 OF 52 USPATFULL on STN DUPLICATE 5
ACCESSION NUMBER: 2002:198674 USPATFULL
TITLE: 32544, a novel human phospholipase C and uses thereof
INVENTOR(S): Meyers, Rachel, Newton, MA, UNITED STATES
Silos-Santiago, Inmaculada, Cambridge, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002106774	A1	20020808
	US 6897056	B2	20050524
APPLICATION INFO.:	US 2001-927112	A1	20010810 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-246808P	20001108 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	4611	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 32544 nucleic acid molecules, which encode novel phospholipase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32544 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32544 gene has been introduced or disrupted. The invention still further provides isolated 32544 proteins, fusion proteins, antigenic peptides and anti-32544 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 43 OF 52 USPATFULL on STN DUPLICATE 6
ACCESSION NUMBER: 2002:185664 USPATFULL
TITLE: 16835, a novel human phospholipase C family member and uses thereof
INVENTOR(S): Meyers, Rachel A., Newton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098577	A1	20020725
	US 6534301	B2	20030318
APPLICATION INFO.:	US 2001-800971	A1	20010306 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-187453P	20000307 (60)
	US 2000-188032P	20000309 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	15 Drawing Page(s)	

LINE COUNT: 5168

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 16835 nucleic acid molecules, which encode novel phospholipase C members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16835 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16835 gene has been introduced or disrupted. The invention still further provides isolated 16835 proteins, fusion proteins, antigenic peptides and anti-16835 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 44 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:251133 USPATFULL

TITLE: Genes regulated in activated T cells

INVENTOR(S): Hopkins, Christopher M., Oakland, CA, UNITED STATES

Peterson, David P., San Jose, CA, UNITED STATES

Cocks, Benjamin G., Sunnyvale, CA, UNITED STATES

Hawkins, Phillip R., Mountain View, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137077	A1	20020926
APPLICATION INFO.:	US 2001-2600	A1	20011025 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-243521P	20001025 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	INCYTE GENOMICS, INC., 3160 Porter Drive, Palo Alto, CA, 94304	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8874	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in activated T cells and which may be used in their entirety or in part to diagnose, to stage, to treat, or to monitor the treatment of a subject with allergy, cancer, chronic graft versus host, infectious, or autoimmune disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 45 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:235413 USPATFULL

TITLE: Troponin I polypeptide fragments and uses thereof

INVENTOR(S): Shi, Qinwei, Etobicoke, CANADA

Liu, Shigui, Mississauga, CANADA

Ling, Mingfu, Toronto, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127602	A1	20020912
APPLICATION INFO.:	US 2001-941997	A1	20010829 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-176546, filed on 21 Oct 1998, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	707		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polypeptides corresponding to stable, circulating degradation products of troponin I (TnI) are described. The fragments comprise a sequence of the N-terminus of native cardiac TnI with 95-115 amino acid and additionally include fragments lacking about the 20-30 N-terminal amino acids. Utilities of these fragments and antibodies thereto include sensitive detection of myocardial infarction and purification of antibodies sensitive to the detection of troponin I degradation products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 46 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:213801 USPATFULL

TITLE: 16816 and 16839, novel human phospholipase C molecules and uses therefor

INVENTOR(S): Meyers, Rachel, Newton, MA, UNITED STATES
Rudolph-Owen, Laura S., Jamaica Plains, MA, UNITED STATES
Tsai, Fong Ying, Newton, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002115178	A1	20020822
APPLICATION INFO.:	US 2001-908664	A1	20010717 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-218675P	20000717 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Carolyn A. Favorito, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	4734	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 16816 or 16839 nucleic acid molecules, which encode novel phospholipase C family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16816 or 16839 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16816 or 16839 gene has been introduced or disrupted. The invention still further provides isolated 16816 or 16839 proteins, fusion proteins, antigenic peptides and anti-16816 or 16839 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 47 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2002:290769 USPATFULL

TITLE: Single-chain polypeptides comprising troponin I N-terminal fragments and **troponin C**

INVENTOR(S): Shi, Qinwei, Etobicoke, CANADA
Liu, Shigui, Mississauga, CANADA
Ling, Mingfu, Etobicoke, CANADA

PATENT ASSIGNEE(S): Spectral Diagnostics, Inc., Toronto, CANADA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6475785	B1	20021105
APPLICATION INFO.:	US 1999-368819		19990805 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1998-176546, filed on 21 Oct 1998 Continuation-in-part of Ser. No. US		

1997-993380, filed on 18 Dec 1997, now patented, Pat.
No. US 6077676

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Caputa, Anthony C.
ASSISTANT EXAMINER: Harris, Alana M.
LEGAL REPRESENTATIVE: Klauber & Jackson
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 815

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to single-chain polypeptides and their genetic sequences comprising a human cardiac troponin I N-terminal fragment and **troponin C**. The N-terminal fragment may or may not have the intact N-terminus. The single-chain polypeptide may be expressed recombinantly, and a linker or spacer polypeptide or peptide may be interposed between the troponin sequences. The single-chain polypeptides have utility as controls or calibrators for troponin assays, for the purification of troponin subunits and as an antigen for the preparation of antibodies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 48 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2001:200224 USPATFULL
TITLE: 16836, a novel human phospholipase C family member and uses thereof
INVENTOR(S): Hunter, John J., Somerville, MA, United States
Meyers, Rachel A., Newton, MA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001039331	A1	20011108
APPLICATION INFO.:	US 2001-822635	A1	20010330 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-193921P	20000331 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LOUIS MYERS, FISH & RICHARDSON P.C., 225 Franklin Street, Boston, MA, 02110-2804	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	5492	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides isolated nucleic acids molecules, designated 16836 nucleic acid molecules, which encode novel phospholipase C members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 16836 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 16836 gene has been introduced or disrupted. The invention still further provides isolated 16836 proteins, fusion proteins, antigenic peptides and anti-16836 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 49 OF 52 USPATFULL on STN

ACCESSION NUMBER: 2000:121619 USPATFULL
TITLE: Manufacture and use of polypeptides tagged using binding molecules
INVENTOR(S): Neri, Dario, Cherry Hinton, United Kingdom
Winter, Gregory Paul, Cambridge, United Kingdom
De Lalla, Claudia, Milan, Italy

PATENT ASSIGNEE(S): Medical Research Council, London, United Kingdom
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6117976		20000912
APPLICATION INFO.:	US 1996-641873		19960502 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 1994-GB2420, filed on 4 Nov 1994		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1993-22772	19931104
	GB 1994-5927	19940325
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Housel, James C.	
ASSISTANT EXAMINER:	Devi, S.	
LEGAL REPRESENTATIVE:	Marshall, O'Toole, Gerstein, Murray & Borun	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 13 Drawing Page(s)	
LINE COUNT:	1574	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Molecules comprise (i) a polypeptide (such as calmodulin) which has calcium-dependent binding affinity for ligand and (ii) another polypeptide, the polypeptides preferably being joined by a peptide bond and produced by recombinant expression from a gene fusion. The molecules are useful in detection, immobilization, targeting and purification, cell-labelling, and band-shift assays for determining binding of a member of a specific binding pair (sbp) for complementary sbp member. For purposes of band-shift assays, polypeptide (i) need not have calcium-dependent binding affinity for a ligand, but should have a dissociation constant for a ligand of 10 nM or less, measured at a pH of between 6 and 9 at 20° C. In an alternative embodiment, a calmodulin-binding polypeptide which is, or is derived from, mastoparan is joined, as polypeptide (i) instead of a binding polypeptide, to the other polypeptide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 50 OF 52 USPATFULL on STN
ACCESSION NUMBER: 97:93887 USPATFULL
TITLE: Phospholipase C homolog
INVENTOR(S): Hawkins, Phillip R., Mountain View, CA, United States
Seilhamer, Jeffrey J., Los Altos Hills, CA, United States
PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5676946		19971014
APPLICATION INFO.:	US 1996-726883		19961004 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-419078, filed on 10 Apr 1995, now patented, Pat. No. US 5587306		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Saidha, Tekchand		
LEGAL REPRESENTATIVE:	Billings, Lucy J.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1270		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides nucleotide and amino acid sequences that identify and encode a novel phospholipase C homolog (plch and PLCH). The

present invention also provides for antisense molecules to the plch nucleotide sequences, expression vectors for the production of purified PLCH, antibodies capable of binding specifically to PLCH, hybridization probes or oligonucleotides for detecting excess PLCH-encoding nucleotide sequences, genetically engineered host cells for the expression of PLCH, diagnostic tests for activated, inflamed, diseased, and hydroxyurea-resistant cells and/or tissues based on PLCH-encoding nucleic acid molecules and antibodies capable of binding specifically to PLCH.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 51 OF 52 USPATFULL on STN

ACCESSION NUMBER: 97:1543 USPATFULL

TITLE: Porcine apamin binding protein/receptor

INVENTOR(S): Ziai, Mohammad R., Montvale, NJ, United States
Sokol, Patricia T., Bedminster, NJ, United States
Chandra, Manik, Paramus, NJ, United States

PATENT ASSIGNEE(S): American Cyanamid Company, Wayne, NJ, United States
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5591824		19970107
APPLICATION INFO.:	US 1994-229511		19940421 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-922307, filed on 30 Jul 1992, now abandoned And Ser. No. US 1992-923095, filed on 30 Jul 1992, now patented, Pat. No. US 5401652		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ulm, John		
LEGAL REPRESENTATIVE:	Hamilton, Brook, Smith & Reynolds, P.C.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	1123		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a protein, isolated from a vertebrate tissue sample, of approximately 80 KDa which specifically binds apamin, and to an approximately 55 KDa presumed degradation product of that protein, as well as antibodies which bind to that protein or to the presumed degradation product.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 52 OF 52 USPATFULL on STN

ACCESSION NUMBER: 96:118520 USPATFULL

TITLE: Phospholipase C homolog

INVENTOR(S): Hawkins, Phillip R., Mountain View, CA, United States
Seilhamer, Jeffrey J., Los Altos Hills, CA, United States

PATENT ASSIGNEE(S): Incyte Pharmaceuticals, Inc., Palo Alto, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5587306		19961224
APPLICATION INFO.:	US 1995-419078		19950410 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wax, Robert A.		
ASSISTANT EXAMINER:	Saidha, Tekchand		
LEGAL REPRESENTATIVE:	Incyte Pharmaceuticals, Inc., Luther, Barbara J.		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)		
LINE COUNT:	1273		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides nucleotide and amino acid sequences that identify and encode a novel phospholipase C homolog (plch and PLCH). The present invention also provides for antisense molecules to the plch nucleotide sequences, expression vectors for the production of purified PLCH, antibodies capable of binding specifically to PLCH, hybridization probes or oligonucleotides for the detecting excess PLCH-encoding nucleotide sequences, genetically engineered host cells for the expression of PLCH, diagnostic tests for activated, inflamed, diseased, and hydroxyurea-resistant cells and/or tissues based on PLCH-encoding nucleic acid molecules and antibodies capable of binding specifically to PLCH.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.